Author:
Bigioni M.,Benzo A.,Irrissuto C.,Lopez G.,Curatella B.,Maggi C. A.,Manzini S.,Crea A.,Caroli S.,Cubadda F.,Binaschi M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference39 articles.
1. World Health Organization. GLOBOCAN (2000) Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0., IARC CancerBase No. 5. IARC Press, Lyon. http://www-dep.iarc.fr/globocan
2. Green MR (2000) Advances in the management of lung cancer. Oncology 14 N.7(suppl N. 4):1–52
3. Wakelee H, Belani CP (2005) Optimizing first-Line treatment options for patients with advanced NSCLC. Oncologist 10:1–10
4. Ancuceanu RV, Istudor RV (2004) Pharmacologically active natural compounds for lung cancer. Altern Med Rev 9(4):402–419
5. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 22(2):330–353
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献